Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss
Publishing timestamp: 2024-06-18 10:22:31
Summary
More U.S. employers are covering GLP-1 drugs for weight loss, with roughly one-third of employer health plans in the U.S. now covering medications like Novo Nordisk's Ozempic and Wegovy. This increase in coverage is a win for patients struggling with high costs and a positive development for the manufacturers. However, some insurance plans are pulling back coverage of weight loss medications, and there are concerns about supply shortages. Venture capital investors are also heavily investing in health-care companies using AI, particularly in administrative applications to address physician burnout and staffing shortages.
Sentiment: POSITIVE
Keywords: biotech and pharmaceuticals, business news, united states, eli lilly and co, social issues, health care industry, labor economy, novo nordisk a/s,